Damora Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses | ||
| Research and development | $678 | $2,463 |
| General and administrative | 1,921 | 3,278 |
| Total operating expenses | 2,599 | 5,741 |
| Loss from operations | (2,599) | (5,741) |
| Other income, net | ||
| Interest income, net | 74 | 257 |
| Foreign exchange transaction gain (loss), net | (6) | 7 |
| Total other income, net | 68 | 264 |
| Loss before income tax expense | (2,531) | (5,477) |
| Income tax expense | (2) | — |
| Net loss | $(2,533) | $(5,477) |
| Net loss per common share, basic and diluted | $(1.92) | $(5.05) |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 1,322,011 | 1,084,509 |
| Other comprehensive income (loss), net of tax | ||
| Currency translation gain (loss) | 203 | (86) |
| Unrealized gain on marketable securities | — | 32 |
| Other comprehensive income (loss), net of tax | 203 | (54) |
| Total comprehensive loss | $(2,330) | $(5,531) |
Galecto, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.